Considering the robust LAG3 expression in the tumor microenvironment and its correlation with poor prognosis in MM and other cancers [23, 43–46], targeting the LAG3-specific inhibitory pathway may enhance anti-MM immunity and have a more favorable therapeutic index. This evidence concerns the gene LAG3 and Miyoshi myopathy.